Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS–CoV‐2 Messenger RNA Vaccination

Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 messenger RNA (mRNA) vaccination. Methods RMD patients (n = 1,377) who received 2‐dose SARS–CoV‐2 mRNA vaccination between Dec...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & Rheumatology 2022-01, Vol.74 (1), p.28-32
Main Authors: Connolly, Caoilfhionn M., Ruddy, Jake A., Boyarsky, Brian J., Barbur, Iulia, Werbel, William A., Geetha, Duvuru, Garonzik‐Wang, Jacqueline M., Segev, Dorry L., Christopher‐Stine, Lisa, Paik, Julie J.
Format: Article
Language:English
Subjects:
2019-nCoV Vaccine mRNA-1273 - administration & dosage
2019-nCoV Vaccine mRNA-1273 - adverse effects
Adult
Allergic reactions
BNT162 Vaccine - administration & dosage
BNT162 Vaccine - adverse effects
COVID-19 - immunology
COVID-19 - prevention & control
Female
Flares
Health services
Humans
Hypersensitivity
Immunization
Immunomodulation
Male
Middle Aged
mRNA
Musculoskeletal diseases
Musculoskeletal Diseases - immunology
Pain
Patients
Prospective Studies
Rheumatic Diseases - immunology
SARS-CoV-2 - immunology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Symptom Flare Up
Vaccination
Vaccines
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 messenger RNA (mRNA) vaccination. Methods RMD patients (n = 1,377) who received 2‐dose SARS–CoV‐2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression. Results Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS–CoV‐2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P 
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.41924